Literature DB >> 19878637

NCCN clinical practice guidelines in oncology: multiple myeloma.

Kenneth C Anderson1, Melissa Alsina, William Bensinger, J Sybil Biermann, Asher Chanan-Khan, Adam D Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M Vose, Donna Weber, Joachim Yahalom, Furhan Yunus.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19878637     DOI： 10.6004/jnccn.2009.0061

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  53 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.

Authors:  George Somlo; Ricardo Spielberger; Paul Frankel; Chatchada Karanes; Amrita Krishnan; Pablo Parker; Leslie Popplewell; Firoozeh Sahebi; Neil Kogut; David Snyder; An Liu; Timothy Schultheiss; Stephen Forman; Jeffrey Y C Wong
Journal:  Clin Cancer Res       Date:  2010-11-03       Impact factor: 12.531

3.  Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.

Authors:  Yadan Wang; Lisha Ai; Guohui Cui; Bhuveshwarnath Gowrea; Mian Li; Yu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

4.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 5.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

6.  Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.

Authors:  Lori F Gentile; George Plitas; Emily C Zabor; Michelle Stempel; Monica Morrow; Andrea V Barrio
Journal:  Ann Surg Oncol       Date:  2017-09-15       Impact factor: 5.344

7.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

8.  Consensus on Surgical Management of Myeloma Bone Disease.

Authors: 
Journal:  Orthop Surg       Date:  2016-08       Impact factor: 2.071

9.  Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma.

Authors:  Junru Liu; Juan Li; Beihui Huang; Dong Zheng; Mei Chen; Zhenhai Zhou; Duorong Xu; Waiyi Zou
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

10.  Male breast cancer: A retrospective study comparing survival with female breast cancer.

Authors:  Li Baojiang; Liu Tingting; Li Gang; Zhang Li
Journal:  Oncol Lett       Date:  2012-07-18       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.